BioSpace News Archive

Proxima Clinical Research (“Proxima CRO”) announced today it is expanding its early phase oncology clinical trials offering with its Early Phase Oncology Network, a group of oncology-specific scientific experts and early phase clinical trials clinics that allows for quick and easy site enrollment and expert insight, feedback, and guidance in first-in-human Phase I and Phase II clinical oncology trials.

BridgeBio Pharma, Inc. today announced the Company’s novel validated muscle tissue-based bioassay, which measures the amount of glycosylated ⍺DG in patients with LGMD2I.

KBI Biopharma, Inc. announced that late in 2022, it successfully released its inaugural First In Human manufacturing batch in compliance with current Good Manufacturing Practice standards in its recently expanded Geneva mammalian cell manufacturing facility.

Inhibikase Therapeutics, Inc. today announced that Milton Werner will present at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™), being held in Gothenburg, Sweden, and virtually, from March 28-April 1, 2023.

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that Axel Hoos, MD, PhD, has joined the NextPoint Board of Directors.

Berkeley Lights, Inc. (Nasdaq: BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome.

ReCode Therapeutics today announced that David Lockhart, Ph.D., President and Chief Scientific Officer of ReCode Therapeutics, will participate in a panel discussion titled “Novel LNPs Targeting Diverse Tissues” at 10:00 a.m. ET on Tuesday, March 28, 2023 at the virtual BMO Biopharma Spotlight Series.

RayzeBio, Inc. today announced the nomination of a first-in-class novel peptide drug candidate against GPC3. As GPC3 is selectively overexpressed in hepatocellular carcinoma and not expressed in normal liver and other tissues, it has a compelling profile for targeted cancer therapy.

Wugen, Inc. today announced that Kumar Srinivasan Ph.D., M.B.A., has been appointed President and Chief Executive Officer, effective March 13, 2023.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its algorithm intended to detect suspected abdominal aortic aneurysm (AAA).